002898 Stock Overview
Sailong Pharmaceutical Group Co., Ltd. researches, develops, produces, markets, and services pharmaceutical intermediates, raw materials, and preparations in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Sailong Pharmaceutical Group Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥9.91 |
| 52 Week High | CN¥14.35 |
| 52 Week Low | CN¥7.70 |
| Beta | 0.081 |
| 1 Month Change | -11.52% |
| 3 Month Change | -7.38% |
| 1 Year Change | -29.06% |
| 3 Year Change | -5.17% |
| 5 Year Change | -20.78% |
| Change since IPO | -8.93% |
Recent News & Updates
Recent updates
Some Shareholders Feeling Restless Over Sailong Pharmaceutical Group Co.,Ltd.'s (SZSE:002898) P/S Ratio
Oct 01
Impressive Earnings May Not Tell The Whole Story For Sailong Pharmaceutical GroupLtd (SZSE:002898)
Apr 26Subdued Growth No Barrier To Sailong Pharmaceutical Group Co.,Ltd. (SZSE:002898) With Shares Advancing 27%
Mar 08Shareholder Returns
| 002898 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -3.4% | -1.9% | -0.6% |
| 1Y | -29.1% | -5.7% | 8.3% |
Return vs Industry: 002898 underperformed the CN Pharmaceuticals industry which returned -5.7% over the past year.
Return vs Market: 002898 underperformed the CN Market which returned 8.3% over the past year.
Price Volatility
| 002898 volatility | |
|---|---|
| 002898 Average Weekly Movement | 6.7% |
| Pharmaceuticals Industry Average Movement | 7.3% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.9% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 002898 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002898's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 483 | Nangui Cai | www.sailong.cn |
Sailong Pharmaceutical Group Co., Ltd. researches, develops, produces, markets, and services pharmaceutical intermediates, raw materials, and preparations in China. The company offers esomeprazole sodium, ornithine aspartate, thymus, argatroban, tigecycline, monosialotetrahexose ganglioside sodium, cerebroprotein hydrolysate, milrinone, parecoxib sodium, tranexamic acid, clindamycin phosphate, pantoprazole sodium products, etc. It provides its products for therapeutic areas, such as cardiovascular, cerebrovascular, nerve, digestive system, proton pump inhibitors, anti-infectives, anti-bleeding drugs, analgesics, and other fields. The company was formerly known as Zhuhai Sailong Pharmaceutical Co.,Ltd.
Sailong Pharmaceutical Group Co.,Ltd. Fundamentals Summary
| 002898 fundamental statistics | |
|---|---|
| Market cap | CN¥1.74b |
| Earnings (TTM) | CN¥1.52m |
| Revenue (TTM) | CN¥303.99m |
1,150x
P/E Ratio5.7x
P/S RatioIs 002898 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002898 income statement (TTM) | |
|---|---|
| Revenue | CN¥303.99m |
| Cost of Revenue | CN¥179.91m |
| Gross Profit | CN¥124.09m |
| Other Expenses | CN¥122.57m |
| Earnings | CN¥1.52m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0086 |
| Gross Margin | 40.82% |
| Net Profit Margin | 0.50% |
| Debt/Equity Ratio | 33.4% |
How did 002898 perform over the long term?
See historical performance and comparisonDividends
0.2%
Current Dividend Yield232%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 03:19 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sailong Pharmaceutical Group Co.,Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yifan Jiang | China Merchants Securities Co. Ltd. |
| Jiaxi Xu | Industrial Securities Co. Ltd. |